MedTrace Logo

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

NCT04976803 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 229

Last updated 2022-08-01

No results posted yet for this study

Summary

This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Conditions

  • Solid Tumor, Unspecified, Adult

Interventions

OTHER

Determination of ATM alteration status.

ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Sponsors & Collaborators

  • Artios Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Melissa Johnson, MD · Sarah Cannon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-28
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04976803 on ClinicalTrials.gov